Becker's Healthcare August 15, 2024
Elizabeth Gregerson

The antiviral drug tecovirimat did not reduce the duration of mpox lesions in a randomized, placebo-controlled trial.

The results were studied among children and adults with mpox in the Democratic Republic of the Congo, according to an Aug. 15 news release from the National Institutes of Health. Detailed results will be released through scientific channels, the NIH said.

...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, Pharma, Pharma / Biotech, Trends
Pharma Pulse 11/25/24: Deepening Patient Relationships, Menopause May Increase Risk of Asthma & more
Axolotl Biosciences Brings Biotech to the Forefront at Formnext 2024
Innovative approach maps gene activity in the living human brain
Trump tariffs could drive up generic drug costs: 5 takeaways
Bridging the Gap: Pharmacists' Role in Advancing Pharmacogenomic Testing Standards

Share This Article